Melatonin in the treatment of perinatal pathology

Abstract

The review presents the results of studies that have shown the effectiveness of melatonin use in the treatment of perinatal pathology based on oxidative stress and associated systemic inflammation with excessive production of pro-inflammatory cytokines. It is shown that the lack or absence of the circadian rhythm of epiphyseal maternal melatonin plays a key role in the development of oxidative stress in the single mother-placenta-fetus functional system. The article summarizes the results of experimental studies that reveal the mechanisms of melatonin influence (antioxidant, anti-inflammatory, immunomodulating), which provide the protection of the fetus from damage caused by oxidative stress and inflammation in pregnancy complications. The article presents the results of the use of melatonin in full-term and premature infants in addition to standard therapy of brain damage as a result of hypoxia-ischemia and asphyxia, respiratory distress syndrome, sepsis, and necrotizing enterocolitis. Currently ongoing international studies should determine the dose, duration, safety profile, short-term and long-term effects of melatonin in newborns of various gestational ages for its inclusion in treatment protocols for perinatal pathology.

Keywords

treatment / melatonin / newborns / perinatal pathology

References

[1] Matveeva EA, Filkina OM, Malyshina AI, et al. Disability infants born weighing less than 1500. Rossijskij vestnik perinatologii i pediatrii. 2017;62(3):66−70. (In Russ.). DOI: 10.21508/1027-4065-2017-62-3-66-70

[2] Матвеева Е.А., Филькина О.М., Малышкина А.И. и др. Инвалидность детей раннего возраста, родившихся с массой тела меньше 1500 г // Российский вестник перинатологии и педиатрии. 2017. Т. 62. № 3. С. 66−70. DOI: 10.21508/1027-4065-2017-62-3-66-70

[3] Zavadenko NN, Davydova LA. Prematurity and low birth weight as risk factors for neurodevelopmental disorders in children. Rossijskij vestnik perinatologii i pediatrii. 2018;63(4):43−51. (In Russ.). DOI: 10.21508/1037-4065-2018-63-4-43-51

[4] Заваденко Н.Н., Давыдова Л.А. Недоношенность и низкая масса тела при рождении как факторы риска нарушений нервно-психического развития у детей // Российский вестник перинатологии и педиатрии. 2018. Т. 63. № 4. С. 43−51. DOI: 10.21508/1037-4065-2018-63-4-43-51

[5] Bellido-Gonzalez M, Dıaz-Lopez MA, Lopez-Criado S, Maldonado-Lozano J. Cognitive functioning and academic achievement in children aged 6–8 years, born at term after intrauterine growth restriction and fetal cerebral redistribution. J Pediatr Psychol. 2017;42(3):345–354. DOI: 10.1093/jpepsy/jsw060

[6] Bellido-Gonzalez M., Dıaz-Lopez M.A., Lopez-Criado S., Maldonado-Lozano J. Cognitive functioning and academic achievement in children aged 6–8 years, born at term after intrauterine growth restriction and fetal cerebral redistribution // J. Pediatr. Psychol. 2017. Vol. 42. No. 3. P. 345–354. DOI: 10.1093/jpepsy/jsw060

[7] van der Pal S, Steinhof M, Grevinga M, et al. Quality of life of adults born very preterm or very low birth weight: A systematic review. Acta Paediatr. 2020;109(10):1974−1988. DOI: 10.1111/apa.15249. doi: 10.1111/apa.15249

[8] van der Pal S., Steinhof M., Grevinga M. et al. Quality of life of adults born very preterm or very low birth weight: A systematic review // Acta Paediatr. 2020. Vol. 109. No. 10. P. 1974−1988. DOI: 10.1111/apa.15249

[9] DuBow A, Mourot A, Tourjman SV. Chiari malformation and attention deficit hyperactivity disorder. Case Rep Med. 2020;2020:2694956. DOI: 10.1155/2020/2694956

[10] DuBow A., Mourot A., Tourjman S.V. Chiari malformation and attention deficit hyperactivity disorder // Case Rep. Med. 2020. Vol. 2020. P. 2694956. DOI: 10.1155/2020/2694956

[11] Gauda EB, McLemore GL. Premature birth, homeostatic plasticity and respiratory consequences of inflammation. Resp Physiol Neurobiol. 2020;274:103337. DOI: 10.1016/j.resp.2019.103337

[12] Gauda E.B., McLemore G.L. Premature birth, homeostatic plasticity and respiratory consequences of inflammation // Resp. Physiol. Neurobiol. 2020. Vol. 274. P. 103337. DOI: 10.1016/j.resp.2019.103337

[13] Ivanov DO, Evsyukova II, Mazzoccoli G, et al. The role of prenatal melatonin in the regulation of childhood obesity. Biology. 2020;9(4):72. DOI: 10.3390/biology9040072

[14] Ivanov D.O., Evsyukova I.I., Mazzoccoli G. et al. The role of prenatal melatonin in the regulation of childhood obesity // Biology. 2020. Vol. 9. No. 4. P. 72. DOI: 10.3390/biology9040072

[15] Perez M, Robbins ME, Revhaugc C, Saugstad OD. Oxygen radical disease in the newborn, revisited: oxidative stress and disease in the newborn period. Free Radic Biol Med. 2019;142:61–72. DOI: 10.1016/j.freeradbiomed.2019.03.035

[16] Perez M., Robbins M.E., Revhaugc C., Saugstad O.D. Oxygen radical disease in the newborn, revisited: oxidative stress and disease in the newborn period // Free Radic. Biol. Med. 2019. Vol. 142. P. 61–72. DOI: 10.1016/j.freeradbiomed.2019.03.035

[17] McAdams RM, Juul SE. The role of cytokines and inflammatory cells in perinatal brain injury. Neurol Res Int. 2012;2012:561494. DOI: 10.1155/2012/561494

[18] McAdams R.M., Juul S.E. The role of cytokines and inflammatory cells in perinatal brain injury // Neurol. Res. Int. 2012. Vol. 2012. P. 561494. DOI: 10.1155/2012/561494

[19] Vasiljevic B, Maglajlic-Djukic S, Gojnic M, et al. New insights into the pathogenesis of perinatal hypoxic-ischemic brain injury. Pediatr Int. 2011;53(4):454–462. DOI: 10.1111/j.1442-200X.2010.03290.x

[20] Vasiljevic B., Maglajlic-Djukic S., Gojnic M. et al. New insights into the pathogenesis of perinatal hypoxic-ischemic brain injury // Pediatr. Int. 2011. Vol. 53. No. 4. P. 454–462. DOI: 10.1111/j.1442-200X.2010.03290.x

[21] Al-Gubory KH, Fowler PA, Garrel C. The roles of cellular reactive oxygen species, oxidative stress and antioxidants in pregnancy outcomes. Intern J Biochem Cell Biol. 2010;42:1634−1650. DOI: 10.1016/j,biocel.2010.06.001

[22] Al-Gubory K.H., Fowler P.A., Garrel C. The roles of cellular reactive oxygen species, oxidative stress and antioxidants in pregnancy outcomes // Intern. J. Biochem. Cell Biol. 2010. Vol. 42. P. 1634−1650. DOI: 10.1016/j,biocel.2010.06.001

[23] Perrone S, Santacroce A, Picardi A, Buonocore G. Fetal programming and early identification of newborns at high risk of free radical-mediated diseases. World J Clin Pediatr. 2016;5(2):172−181. DOI: 10.5409/wjcp.v5.i2.172

[24] Perrone S., Santacroce A., Picardi A., Buonocore G. Fetal programming and early identification of newborns at high risk of free radical-mediated diseases // World J. Clin. Pediatr. 2016. Vol. 5. No. 2. P. 172−181. DOI: 10.5409/wjcp.v5.i2.172

[25] Aulamazyan EK, Evsyukova II, Yarmolinskaya MI. The role of melatonin in development of gestational diabetesmellitus. Journal of Obstetrics and Women’s Diseases. 2018;67(1):85−91. (In Russ.). DOI: 10.17816/JOWD67185-91

[26] Айламазян Э.К., Евсюкова И.И., Ярмолинская М.И. Роль мелатонина в развитии гестационного сахарного диабета // Журнал акушерства и женских болезней. 2018. Т. 67. № 1. С. 85−91. DOI: 10.17816/JOWD67185-91

[27] Forrestel AC, Miedlich SU, Yurcheshen M, et al. Chronomedicine and type 2 diabetes: shining some light on melatonin. Diabetologia. 2017;60(5):808−822. DOI: 10.1007/s00125-016-4175-1

[28] Forrestel A.C., Miedlich S.U., Yurcheshen M.Y. et al. Chronomedicine and type 2 diabetes: shining some light on melatonin // Diabetologia. 2017. Vol. 60. No. 5. P. 808−822. DOI: 10.1007/s00125-016-4175-1

[29] Bouchlariotou S, Liakopoulos V, Giannopoulou M, et al. Melatonin secretion is impaired in women with preeclampsia and abnormal circadian blood pressure rhythm. Ren Fail. 2014;36(7):1001−1007. DOI: 10.3109/0886022X.2014.926216

[30] Bouchlariotou S., Liakopoulos V., Giannopoulou M. et al. Melatonin secretion is impaired in women with preeclampsia and abnormal circadian blood pressure rhythm // Ren. Fail. 2014. Vol. 36. No. 7. P. 1001−1007. DOI: 10.3109/0886022X.2014.926216

[31] Nehme PA, Amaral FG, Middleton B, et al. Melatonin profiles during the third trimester of pregnancy and health status in the offspring among day and night workers: A case series. Neurobiol Sleep Circadian Rhythms. 2019;6:70−76. DOI: 10.1016/j.nbscr.2019.04.001

[32] Nehme P.A., Amaral F.G., Middleton B. et al. Melatonin profiles during the third trimester of pregnancy and health status in the offspring among day and night workers: A case series // Neurobiol. Sleep. Circadian. Rhythms. 2019. Vol. 6. P. 70−76. DOI: 10.1016/j.nbscr.2019.04.001

[33] Hsu C-N, Tain Y-L. Light and circadian signaling pathway in pregnancy: Programming of adult health and disease. Int J Mol Sci. 2020;21:2232. DOI: 10.3390/ijms21062232

[34] Hsu C.N., Tain Y.L. Light and circadian signaling pathway in pregnancy: Programming of adult health and disease // Int. J. Mol. Sci. 2020. Vol. 21. No. 6. P. 2232. DOI: 10.3390/ijms21062232

[35] Richter HJ, Hansell JA, Raut S, Glussani DA. Melatonin improves placental efficiency and birth weight increases the placental expression of antioxidant enzymes in undernourished pregnancy. J Pineal Res. 2009;46(4):357−364. DOI: 10.1111/j,1600-079X.2009.00671x

[36] Richter H.J., Hansell J.A., Raut S., Glussani D.A. Melatonin improves placental efficiency and birth weight increases the placental expression of antioxidant enzymes in undernourished pregnancy // J. Pineal. Res. 2009. Vol. 46. No. 4. P. 357−364. DOI: 10.1111/j,1600-079X.2009.00671x

[37] Reiter RJ, Rosales-Corral S, Tan DX, et al. Melatonin as a mitochondria-targeted antioxidant: one of evolution’s best ideas. Cell Mol Life Sci. 2017;74(21):3863−3881. DOI: 10.1007/s00018-017-2609-7

[38] Reiter R.J., Rosales-Corral S., Tan D.X. et al. Melatonin as a mitochondria-targeted antioxidant: one of evolution’s best ideas // Cell Mol. Life Sci. 2017. Vol. 74. No. 21. P. 3863−3881. DOI: 10.1007/s00018-017-2609-7

[39] Reiter RJ, Tan DX, Korkmaz A, Rosales-Corral SA. Melatonin and stabile circadian rhythms optimize maternal, placental and fetal physiology. Hum Reprod Update. 2014;20(2):293−307. DOI: 10.1016/j.fertnstert.2014.06.014

[40] Reiter R.J., Tan D.X., Korkmaz A., Rosales-Corral S.A. Melatonin and stabile circadian rhythms optimize maternal, placental and fetal physiology // Hum. Reprod. Update. 2014. Vol. 20. No. 2. P. 293−307. DOI: 10.1016/j.fertnstert.2014.06.014

[41] Galano A, Tan DX, Reiter RJ. Melatonin: A versatile protector against oxidative DNA damage. Molecules. 2018;23(3):530. DOI: 10.3390/molecules23030530

[42] Galano A., Tan D.X., Reiter R.J. Melatonin: A versatile protector against oxidative DNA damage // Molecules. 2018. Vol. 23. No. 3. P. 530. DOI: 10.3390/molecules23030530

[43] Evsyukova II, Kvetnoy IM. Melatonin andcircadian rhythms in the system “mother-placenta-fetus”. Molekuljarnaja medicina. 2018;16(6):9−13. (In Russ.). DOI: 10.29296/24999490-2018-06-02

[44] Евсюкова И.И., Кветной И.М. Мелатонин и циркадианные ритмы в системе мать – плацента – плод // Молекулярная медицина. 2018. Т. 16. № 6. С. 9−13. DOI: 10.29296/24999490-2018-06-02

[45] Tain YL, Huang LT., Hsu CN. Developntal programming of adult disease: reprogramming by melatonin? Nt J Mol Sci. 2017;18:426−437. DOI: 10/3390/ijms18020426

[46] Tain Y.L., Huang L.T., Hsu C.N. Developntal programming of adult disease: reprogramming by melatonin? // Nt. J. Mol. Sci. 2017. Vol. 18. P. 426−437. DOI: 10/3390/ijms18020426

[47] Gitto E, Marseglia L, Manti S, et al. Protective role of melatonin in neonatal diseases. Oxid Med Cell Longev. 2013;2013:980374. DOI: 10.1155/2013/980374

[48] Gitto E., Marseglia L., Manti S. et al. Protective role of melatonin in neonatal diseases // Oxid Med. Cell Longev. 2013. Vol. 2013. P. 980374. DOI: 10.1155/2013/980374

[49] Kennaway DJ, Flanagan DE, Moore V, et al. The impact of fetal size and length of gestation on 6-sulphatoxymelatonin excretion in adult life. J Pineal Res. 2001;30(3):188−192. DOI: 10.1034/j.1600-079x.2001.300308.x

[50] Kennaway D.J., Flanagan D.E., Moore V. et al. The impact of fetal size and length of gestation on 6-sulphatoxymelatonin excretion in adult life // J. Pineal. Res. 2001. Vol. 30. No. 3. P. 188−192. DOI: 10.1034/j.1600-079x.2001.300308.x

[51] Tauman R, Zisapel N, Laudon M, et al. Melatonin production in infants. Pediatr Neurol. 2002;26(5):379−382. DOI: 10.1016/s0887-8994(01)00417-9

[52] Tauman R., Zisapel N., Laudon M. et al. Melatonin production in infants // Pediatr. Neurol. 2002. Vol. 26. No. 5. P. 379−382. DOI: 10.1016/s0887-8994(01)00417-9

[53] Biran V, Decobert F, Bednarek N, et al. Melatonin levels in preterm and term infants and their mothers. Int J Mol Sci. 2019;20(9):2077. DOI: 10.3390/ijms20092077

[54] Biran V., Decobert F., Bednarek N. et al. Melatonin levels in preterm and term infants and their mothers // Int. J. Mol. Sci. 2019. Vol. 20. No. 9. P. 2077. DOI: 10.3390/ijms20092077

[55] D’Angelo G, Chimenz R, Reiter RJ, Gitto E. Use of melatonin in oxidative stress related neonatal diseases. Antioxidants (Basel). 2020;9(6):477. DOI: 10.3390/antiox9060477

[56] D’Angelo G., Chimenz R., Reiter R.J., Gitto E. Use of melatonin in oxidative stress related neonatal diseases // Antioxidants (Basel). 2020. Vol. 9. No. 6. P. 477. DOI: 10.3390/antiox9060477

[57] Aversa S, Pellegrino S, Barberi I, et al. Potential utility of melatonin as an antioxidant during pregnancy and in the perinatal period. J Matern Fetal Neonatal Med. 2012;25(3):207−221. DOI: 10.3109/14767058.2011.573827

[58] Aversa S., Pellegrino S., Barberi I. et al. Potential utility of melatonin as an antioxidant during pregnancy and in the perinatal period // J. Matern. Fetal. Neonatal. Med. 2012. Vol. 25. No. 3. P. 207−221. DOI: 10.3109/14767058.2011.573827

[59] Alonso-Alconada D, Alvarez A, Arteaga O, et al. Neuroprotective effect of melatonin: a novel therapy against perinatal hypoxia-ischemia. Int J Mol Sci. 2013;14(5):9379–9395. DOI: 10.3390/ijms14059379

[60] Alonso-Alconada D., Alvarez A., Arteaga O. et al. Neuroprotective effect of melatonin: a novel therapy against perinatal hypoxia-ischemia // Int. J. Mol. Sci. 2013. Vol. 14. No. 5. P. 9379–9395. DOI: 10.3390/ijms14059379

[61] Biran V, Phan Duy A, Decobert F, et al. Is melatonin ready to be used in preterm infants as a neuroprotectant? Dev Med Child Neurol. 2014;56(8):717−723. DOI: 10.1111/dmcn.12415

[62] Biran V., Phan Duy A., Decobert F. et al. Is melatonin ready to be used in preterm infants as a neuroprotectant? // Dev. Med. Child. Neurol. 2014. Vol. 56. No. 8. P. 717−723. DOI: 10.1111/dmcn.12415

[63] Colella M, Biran V, Baud O. Melatonin and the newborn brain. Early Human Development. 2016;102:1−3. DOI: 10.1016/j.earlhudev.2016.09.001

[64] Colella M., Biran V., Baud O. Melatonin and the newborn brain // Early Hum. Dev. 2016. Vol. 102. P. 1−3. DOI: 10.1016/j.earlhudev.2016.09.001

[65] Paprocka J, Kijonka M, Rzepka B, Sokół M. Melatonin in hypoxic-ischemic brain injury in term and preterm babies. Int J Endocrinol. 2019;2019:9626715. DOI: 10.1155/2019/9626715

[66] Paprocka J., Kijonka M., Rzepka B., Sokol M. Melatonin in hypoxic-ischemic brain injury in term and preterm babies // Intern. J. Endocrinol. 2019. Vol. 2019. P. 9626715. DOI: 10.1155/2019/9626715

[67] Hassell KJ, Ezzati M, Alonso-Alconada D, et al. New horizons for newborn brain protection: Enhancing endogenous neuroprotection. Arch Dis Child Fetal Neonatal Ed. 2015;100(6):F541–552. DOI: 10.1136/archdischild-2014-306284

[68] Hassell K.J., Ezzati M., Alonso-Alconada D. et al. New horizons for newborn brain protection: Enhancing endogenous neuroprotection // Arch. Dis. Child. Fetal Neonatal. Ed. 2015. Vol. 100. No. 6. P. F541–552. DOI: 10.1136/archdischild-2014-306284

[69] Hendaus MA, Jomha FA, Alhammadi AH. Melatonin in the management of perinatal hypoxic-ischemic encephalopathy: light at the end of the tunnel? Neuropsychiatr Dis Treat. 2016;12:2473–2479. DOI: 10.2147/NDT. S115533

[70] Hendaus M.A., Jomha F.A., Alhammadi A.H. Melatonin in the management of perinatal hypoxic-ischemic encephalopathy: light at the end of the tunnel? // Neuropsychiatr. Dis. Treat. 2016. Vol. 12. P. 2473–2479. DOI: 10.2147/NDT. S115533

[71] Wang Q, Lv H, Lu L, et al. Neonatal hypoxic-ischemic encephalopathy: emerging therapeutic strategies based on pathophysiologic phases of the injury. J Matern Fetal Neonatal Med. 2019;32(21):3685−3692. DOI: 10.1080/14767058.2018.1468881

[72] Wang Q., Lv H., Lu L. et al. Neonatal hypoxic-ischemic encephalopathy: Emerging therapeutic strategies based on pathophysiologic phases of the injury // J. Matern. Fetal. Neonatal. Med. 2019. Vol. 32. No. 21. P. 3685−3692. DOI: 10.1080/14767058.2018.1468881

[73] Lawn JE, Kerber K, Enweronu-Laryea C, Cousens S. 3.6 million neonatal deaths-what is progressing and what is not? Semin Perinatol. 2010;34(6):371–386. DOI: 10.1053/j.semperi.2010.09.011

[74] Lawn J.E., Kerber K., Enweronu-Laryea C., Cousens S. 3.6 million neonatal deaths-what is progressing and what is not? // Semin. Perinatol. 2010. Vol. 34. No. 6. P. 371–386. DOI: 10.1053/j.semperi.2010.09.011

[75] Cotten SM, Shankaran S. Hypothermia for hypoxic-ischemic encephalopathy. Expert Rev Obstet Gynecol. 2010;5(2):227−239. DOI: 10.1586/eog.10.7

[76] Cotten S.M., Shankaran S. Hypothermia for hypoxic-ischemic encephalopathy // Expert. Rev. Obstet. Gynecol. 2010. Vol. 5. No. 2. P. 227−239. DOI: 10.1586/eog.10.7

[77] Jacobs SE, Berg M, Hunt R, et al. Cooling for newborns with hypoxic ischemic encephalopathy. Cochrane Database Syst Rev. 2013;2013(1):CD003311. DOI: 10.1002/14651858.CD003311.pub3

[78] Jacobs S.E., Berg M., Hunt R. et al. Cooling for newborns with hypoxic ischemic encephalopathy // Cochrane Database Syst. Rev. 2013. Vol. 2013. No. 1. P. CD003311. DOI: 10.1002/14651858.CD003311.pub3

[79] Robertson NJ, Martinello K, Lingam I, et al. Melatonin as an adjunct to therapeutic hypothermia in a piglet model of neonatal encephalopathy: A translational study. Neurobiol Dis. 2019;121:240–251. DOI: 10.1016/j.nbd.2018.10.004

[80] Robertson N.J., Martinello K., Lingam I. et al. Melatonin as an adjunct to therapeutic hypothermia in a piglet model of neonatal encephalopathy: A translational study // Neurobiol. Dis. 2019. Vol. 121. P. 240–251. DOI: 10.1016/j.nbd.2018.10.004

[81] Aly Н, Elmahdy H, El-Dib M, et al. Melatonin use for neuroprotection in perinatal asphyxia: A randomized controlled pilot study. J Perinatol. 2015;35(3):186−191. DOI: 10.1038/jp.2014.186

[82] Aly Н., Elmahdy H., El-Dib M. et al. Melatonin use for neuroprotection in perinatal asphyxia: A randomized controlled pilot study // J. Perinatol. 2015. Vol. 35. No. 3. P. 186−191. DOI: 10.1038/jp.2014.186

[83] Balduini W, Weiss MD, Carloni S, et al. Melatonin pharmacokinetics and dose extrapolation after enteral infusion n neonates subjected to hypothermia. J Pineal Res. 2019;66(4):e12565. DOI: 10.1111/jpi.12565

[84] Balduini W., Weiss M.D., Carloni S. et al. Melatonin pharmacokinetics and dose extrapolation after enteral infusion n neonates subjected to hypothermia // J. Pineal. Res. 2019. Vol. 66. No. 4. P. e12565. DOI: 10.1111/jpi.12565

[85] Fulia F, Gitto E, Cuzzocrea S, et al. Increased levels of malondialdehyde and nitrite/nitrate in the blood of asphyxiated newborns: reduction by melatonin. J Pineal Res. 2001;31(4):343−349. DOI: 10.1034/j.1600-079x.2001.310409.x

[86] Fulia F., Gitto E., Cuzzocrea S. et al. Increased levels of malondialdehyde and nitrite/nitrate in the blood of asphyxiated newborns: reduction by melatonin // J. Pineal. Res. 2001. Vol. 31. No. 4. P. 343−349. DOI: 10.1034/j.1600-079x.2001.310409.x

[87] Ahmad QM, Chishti AL, Waseem N. Role of melatonin in management of hypoxic ischemic encephalopathy in newborns: a randomized control trial. J Pak Med Assoc. 2018;68(8):1233–1237.

[88] Ahmad Q.M., Chishti A.L., Waseem N. Role of melatonin in management of hypoxic ischemic encephalopathy in newborns: a randomized control trial // J. Pak. Med. Assoc. 2018. Vol. 68. No. 8. P. 1233–1237.

[89] Merchant N, Azzopardi DV, Hawwa AF, et al. Pharmacokinetics of melatonin in preterm infants. Br J Clin Pharmacol. 2013;76(5):725−733. DOI: 10.1111/bcp.12092

[90] Merchant N., Azzopardi D.V., Hawwa A.F. et al. Pharmacokinetics of melatonin in preterm infants // Br. J. Clin. Pharmacol. 2013. Vol. 76. No. 5. P. 725−733. DOI: 10.1111/bcp.12092

[91] Carloni S, Proietti F, Rocchi M, et al. Melatonin pharmacokinetics following oral administration in preterm neonates. Molecules. 2017;22(12):2115. DOI: 10.3390/molecules22122115

[92] Carloni S., Proietti F., Rocchi M. et al. Melatonin pharmacokinetics following oral administration in preterm neonates // Molecules. 2017. Vol. 22. No. 12. P. 2115. DOI: 10.3390/molecules22122115

[93] Gitto E, Reiter RJ, Amodio A, et al. Early indicators of chronic lung disease in Preterm infants with respiratory distress syndrome and their inhibition by melatonin. J Pineal Res. 2004;36(4):250−255. DOI: 10.1111/j.1600-079X.2004.00124.x

[94] Gitto E., Reiter R.J., Amodio A. et al. Early indicators of chronic lung disease in Preterm infants with respiratory distress syndrome and their inhibition by melatonin // J. Pineal. Res. 2004. Vol. 36. No. 4. P. 250−255. DOI: 10.1111/j.1600-079X.2004.00124.x

[95] Aversa S, Marseglia L, Manti S, et al. Ventilation strategies for preventing oxidative stress-induced injury in preterm infants with respiratory disease: An update. Paediatr Respir Rev. 2016;17:71–79. DOI: 10.1016/j.prrv.2015.08.015

[96] Aversa S., Marseglia L., Manti S. et al. Ventilation strategies for preventing oxidative stress-induced injury in preterm infants with respiratory disease: An update // Paediatr. Respir. Rev. 2016. Vol. 17. P. 71–79. DOI: 10.1016/j.prrv.2015.08.015

[97] Gitto E, Reiter RJ, Sabatino G, et al. Correlation among cytokines, bronchopulmonary dysplasia and modality of ventilation in preterm newborns: Improvement with melatonin treatment. J Pineal Res. 2005;39(3):287−293. DOI: 10.1111/j.1600-079X.2005.00251.x

[98] Gitto E., Reiter R.J., Sabatino G. et al. Correlation among cytokines, bronchopulmonary dysplasia and modality of ventilation in preterm newborns: Improvement with melatonin treatment // J. Pineal. Res. 2005. Vol. 39. No. 3. P. 287–293. DOI: 10.1111/j.1600-079X.2005.00251.x

[99] Suleymanoglu S, Cekmez F, Cetinkaya M, et al. Protective effects of melatonin therapy in model for neonatal hyperoxic lung injury. Altern Ther Med. 2014;20(5):24−29.

[100] Suleymanoglu S., Cekmez F., Cetinkaya M. et al. Protective effects of melatonin therapy in model for neonatal hyperoxic lung injury // Altern. Ther. Med. 2014. Vol. 20. No. 5. P. 24−29.

[101] de Souza DC, Brandão MB, Piva JP. From the international pediatric sepsis conference 2005 to the Sepsis-3 consensus. Rev Bras Ter Intensiva. 2018;30(1):1−5. DOI: 10.5935/0103-507X.20180005

[102] de Souza D.C., Brandão M.B., Piva J.P. From the international pediatric sepsis conference 2005 to the Sepsis-3 consensus // Rev. Bras. Ter. Intensiva. 2018. Vol. 30. No. 1. P. 1−5. DOI: 10.5935/0103-507X.20180005

[103] Gitto E, Karbownik M, Reiter RJ, et al. Effects of melatonin treatment in septic newborns. Pediatr Res. 2001;50(6):756–760. DOI: 10.1203/00006450-200112000-00021

[104] Gitto E., Karbownik M., Reiter R.J. et al. Effects of melatonin treatment in septic newborns // Pediatr. Res. 2001. Vol. 50. No. 6. P. 756–760. DOI: 10.1203/00006450-200112000-00021

[105] El Gendy FM ,El Hawy MA, Hassan MG. Beneficial effect of melatonin in the treatment of neonatal sepsis. J Matern Fetal Neonatal Med. 2018;31(17):2299−2303. DOI: 10.1080/14767058.2017.1342794

[106] El-Gendy F.M., El-Hawy M.A., Hassan M.G. Beneficial effect of melatonin in the treatment of neonatal sepsis // J. Matern. Fetal Neonatal. Med. 2018. Vol. 31. No. 17. P. 2299−2303. DOI: 10.1080/14767058.2017.1342794

[107] EL Frargy M, EL Sharkawy HM, Attia GF. Use of melatonin as an adjuvant therapy in neonatal sepsis. J Neonatal Perinatal Med. 2015;8(3):227−232. DOI: 10.3233/NPM-15814072

[108] EL Frargy M., EL Sharkawy H.M., Attia G.F. Use of melatonin as an adjuvant therapy in neonatal sepsis // J. Neonatal. Perinatal. Med. 2015. Vol. 8. No. 3. P. 227−232. DOI: 10.3233/NPM-15814072

[109] Henderson R, Kim S, Lee E. Use of melatonin as adjunctive therapy in neonatal sepsis: A systematic review and meta-analysis complement. Ther Med. 2018;39:131−136. DOI: 10.1016/j.ctim.2018.06.002

[110] Henderson R., Kim S., Lee E. Use of melatonin as adjunctive therapy in neonatal sepsis: A systematic review and meta-analysis complement // Ther. Med. 2018. Vol. 39. P. 131−136. DOI: 10.1016/j.ctim.2018.06.002

[111] El Kabbany ZA, El Farghali OG, Khafagy SM, et al. Melatonin as an adjuvant therapy in preterm infants with neonatal sepsis, randomized trial. Egypt Pediatr Assoc Gazette. 2020;68:2. DOI: 10.1186/s43054-019-0013-7

[112] El Kabbany Z.A., El Farghali O.G., Khafagy S.M. et al. Melatonin as an adjuvant therapy in preterm infants with neonatal sepsis, randomized trial // Egypt Pediatr. Assoc. Gazette. 2020. Vol. 68. P. 2. DOI: 10.1186/s43054-019-0013-7

[113] Perrone S, Tataranno ML, Santacroce A, et al. The role of oxidative stress on necrotizing enterocolitis in very low birth weight infants. Curr Pediatr Rev Actions. 2014;10(3):202−207.

[114] Perrone S., Tataranno M.L., Santacroce A. et al. The role of oxidative stress on necrotizing enterocolitis in very low birth weight infants // Curr. Pediatr. Rev. Actions. 2014. Vol. 10. No. 3. P. 202−207.

[115] Aydemir С, Dilli D, Uras N, et al. Total oxidant status and oxidative stress are increased in infants with necrotizing enterocolitis. J Pediatr Surg Actions. 2011;46(11):2096−2100. DOI: 10.1016/j.jpedsurg.2011.06.032

[116] Aydemir С., Dilli D., Uras N. et al. Total oxidant status and oxidative stress are increased in infants with necrotizing enterocolitis // J. Pediatr. Surg. Actions. 2011. Vol. 46. No. 11. P. 2096−2100. DOI: 10.1016/j.jpedsurg.2011.06.032

[117] Marseglia L, D’Angelo G, Manti S, et al. Oxidative stress-mediated damage in newborns with necrotizing enterocolitis: A possible role of melatonin. Am J Perinatol. 2015;32(10):905−909. DOI: 10.1055/s-0035-1547328

[118] Marseglia L., D’Angelo G., Manti S. et al. Oxidative stress-mediated damage in newborns with necrotizing enterocolitis: A possible role of melatonin // Am. J. Perinatol. 2015. Vol. 32. No. 10. P. 905−909. DOI: 10.1055/s-0035-1547328

[119] Gitto E, Aversa S, Salpietro CD, et al. Pain in neonatal intensive care: Role of melatonin as an analgesic antioxidant. J Pineal Res. 2012;52(3):291−295. DOI: 10.1111/j.1600-079X.2011.00941

[120] Gitto E., Aversa S., Salpietro C.D. et al. Pain in neonatal intensive care: Role of melatonin as an analgesic antioxidant // J. Pineal. Res. 2012. Vol. 52. No. 3. P. 291−295. DOI: 10.1111/j.1600-079X.2011.00941

[121] Gitto E, Romeo C, Reiter RJ, et al. Melatonin reduces oxidative stress in surgical neonates. J Pediatr Surg. 2004;39(2):184−189. DOI: 10.1016/j.jpedsurg.2003.10.003

[122] Gitto E., Romeo C., Reiter R.J. et al. Melatonin reduces oxidative stress in surgical neonates // J. Pediatr. Surg. 2004. Vol. 39. No. 2. P. 184−189. DOI: 10.1016/j.jpedsurg.2003.10.003

[123] Marseglia L, Manti S, D’Angelo G, et al. Melatonin for the newborn. J Pediatr Neonat Individ Med. 2014;3(2):e030232. DOI: 10.7363/030232

[124] Marseglia L., Manti S., D’Angelo G. et al. Melatonin for the newborn // J. Pediatr. Neonat. Individ. Med. 2014. Vol. 3. No. 2. P. e030232. DOI: 10.7363/030232

[125] Garg BD. Melatonin as a neuroprotective agent in hypoxic ischemic encephalopathy: Is it beneficial. EC Paediatrics. 2019;8(1):53−60. [cited 3 Nov 2021] Available from: https://www.researchgate.net/publication/330106948_EC_Paediatrics_Review_Article_Melatonin_as_a_Neuroprotective_Agent_in_Hypoxic_Ischemic_Encephalopathy_Is_it_Beneficial

[126] Garg B.D. Melatonin as a neuroprotective agent in hypoxic ischemic encephalopathy: Is it beneficial // EC Paediatrics. 2019. Vol. 8. No. 1. P. 53−60. [дата обращения 03.11.2021]. Доступ по ссылке: https://www.researchgate.net/publication/330106948_EC_Paediatrics_ Review_Article_Melatonin_as_a_Neuroprotective_Agent_in_Hypoxic_Ischemic_Encephalopathy_Is_it_Beneficial

[127] Tarocco A, Caroccia N, Morrciano G, et al. Melatonin as a master regulator of cell death and inflammation: molecular mechanisms and clinical implications for newborn care. Cell Death Disease. 2019;10(4):317. DOI: 10.1038/s41419-019-1556-7

[128] Tarocco A., Caroccia N., Morrciano G. et al. Melatonin as a master regulator of cell death and inflammation: molecular mechanisms and clinical implications for newborn care // Cell Death. Disease. 2019. Vol. 10. No. 4. P. 317. DOI: 10.1038/s41419-019-1556-7

RIGHTS & PERMISSIONS

Eсо-Vector